FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(h)	STA
Instruction 1(b).	

ATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* WILSON JAMES N						2. Issuer Name and Ticker or Trading Symbol CORCEPT THERAPEUTICS INC [CORT]										ck all app	k all applicable)		ing Person(s) to Issue 10% Owne			
l .	CEPT TH	IERAPEUTICS	(Middl	e)		3. Date of Earliest Transaction (Month/Day/Year) 08/01/2011										Offic belo	icer (give title ow)		Othe belo	er (specify w)		
149 COMMONWEALTH DRIVE					4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)										6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) MENLO	PARK C	A S	9402	5	_										y		rm filed by One Reporting Porm rm filed by More than One R rson					
(City)	(5	State) ((Zip)																			
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																					
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye				Year)	2A. Deemed Execution Date, if any (Month/Day/Year)		e, 1	3. Transaction Code (Instr. 8) 4. Securit Disposed			urities <i>A</i> sed Of (Acquired D) (Instr.	(A) or 3, 4 and 5	Benefic Owned		es ially Following	Form (D) o	vnership n: Direct r Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership			
								[v	Amou	nt	(A) or (D) Price			Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)		
Common Stock 08/01/2011					11				S		10,0	00(1)	D	\$3.4724(2)		1,994,511		I		By Trust		
Common Stock 08/01/201					11	1			S		5,00	00(1)	D	D \$3.4093 ⁽³⁾		911,774			I	By Family Partnership		
		Ta	able	II - Deriva (e.g., p										neficial curities		Owned						
Derivative Security or Exercise (Month/Day/Year) Frice of Derivative Security Date (Month/Day/Year) Execution Date, if any (Month/Day/Year) Security Securit					action (Instr.	5. Num of Derive Secur Acqui (A) or Dispo of (D) (Instr. and 5	ative rities ired sed	Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4) Amoun or Numbe of Title Shares		De Se (Ir	Price of erivative ecurity istr. 5)	9. Numbe derivative Securities Beneficial Owned Following Reported Transacti (Instr. 4)	e S Illy	10. Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership t (Instr. 4)				

Explanation of Responses:

- 1. The sale is made pursuant to terms of a 10b5-1 plan in effect at the time of sale of the shares.
- 2. Represents the weighted average sale price for the entire number of shares sold. The sale prices range from \$3.37 to \$3.57 per share. Full information on the numbers of shares sold at each sale price is available upon request.
- 3. Represents the weighted average sale price for the entire number of shares sold. The sale prices range from \$3.37 to \$3.55 per share. Full information on the numbers of shares sold at each sale price is available upon request.

Remarks:

/s/ Joseph K. Belanoff, CEO of

Corcept Therapeutics

08/01/2011

Inocrporated attorney-in-fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.